SIETES :: 93213 citas

Resultados de la búsqueda por ALEMTUZUMAB REFINAR BÚSQUEDA

1.

Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]

2.

Anónimo. Maladies auto-immunes d'origine médicamenteuse. Prescrire 2017;37:346-53. [Ref.ID 101654]

3.

Anónimo. Médicaments de la sclérose en plaques et leucoencéphalopathies multifocales progressives. Prescrire 2017;37:24. [Ref.ID 101363]

4.

Anónimo. Daclilzumab (Zinbryta) for multiple sclerosis. Med Lett Drugs Ther 2016;58:117-9. [Ref.ID 100792]

5.

Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ 2016;354:i3518. [Ref.ID 100715]

6.

The 3C Study Collaborative Group. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet 2014;384:1684-90. [Ref.ID 98323]

7.

Gold R, Glovannoni G, Selmaj KH, Havrdova E, Montalban X, Radue E-W, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G, for the SELECT study investigators. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 2013;381:2167-75. [Ref.ID 95716]

8.

Saldha S, Calabresi PA. Anti-interleukin-2 receptor alpha for multiple sclerosis?. Lancet 2013;381:2141-3. [Ref.ID 95708]

9.

Anónimo. Immunomodulatory medicines: progressive multifocal leuko-encephalopathy. Australia. WHO Drug Information 2013;27:16-7. [Ref.ID 95227]

10.

Laurance J. Genzyme restores some access to MS drug after neurologists protest. BMJ 2013;346:1. [Ref.ID 94921]

11.

Thompson AJ, Giovannoni G. Removal of alemtuzumab for patients with aggressive MS. BMJ 2013;346:10. [Ref.ID 94828]

12.

Shaughnessy A. Magic bullets with a hefty price tag. BMJ 2012;345:18-9. [Ref.ID 94244]

13.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DAS, for the CARE-MS II Investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39. [Ref.ID 94117]

14.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DAS, for the CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1818-29. [Ref.ID 94116]

15.

Sprenger T, Kappos L. Alemtuzumab for multiple sclerosis: who and when to treat?. Lancet 2012;380:1795-7. [Ref.ID 94115]

16.

Anónimo. Alemtuzumab for multiple sclerosis. Lancet 2012;380:1792. [Ref.ID 94114]

17.

Anónimo. New drugs for multiple sclerosis. Med Lett Drugs Ther 2012;54:89-91. [Ref.ID 94048]

18.

Mayor S. Presurgery chemo may improve colon cancer survival. BMJ 2012;345:4. [Ref.ID 94037]

19.

Laurance J. Neurologists appeal to health secretary over withdrawal of drug. BMJ 2012;345:2. [Ref.ID 94035]

20.

Markmann JF, Fishman JA. Alentuzumab in kidney-transplant recipients. N Engl J Med 2011;364:1968-9. [Ref.ID 90613]